COVID-19

Views & Analysis
Surviving as a rare disease biotech during COVID-19

Surviving as a rare disease biotech during COVID-19

With trial delays, social distancing, and falls in charitable funding, the coronavirus pandemic presents some serious challenges for nonprofit orphan disease biotechs like Cure Rare Disease

News
Gilead Sciences

Japan approves Gilead's COVID-19 drug remdesivir

Japan’s regulator has quickly approved Gilead’s remdesivir for patients with severe COVID-19, after the FDA allowed its use as an emergency treatment for the disease earlier this month.